US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Pliant Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
News headline image
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
< Previous 1 2 3 Next >